Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 8/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 6/20 | 0.37 |
| ▸ | EGFR | P00533 | 4/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 3/20 | 0.34 |
| ▸ | ABL2 | P42684 | 3/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20981822 | 0.93 | ADK (0.46) | ADKSLC29A1HASPINSRCEGFR | |
| SCHEMBL20981811 | 0.93 | ADK (0.46) | ADKSLC29A1HASPINSRCEGFR | |
| SCHEMBL20981800 | 0.88 | ADK (0.49) | ADKSLC29A1HASPINSRCEGFR | |
| SCHEMBL29989281 | 0.86 | ADK (0.44) | ADKSLC29A1HASPINSRCEGFR | |
| SCHEMBL20981725 | 0.86 | ADK (0.44) | ADKSLC29A1HASPINSRCEGFR | |
| SCHEMBL28800796 | 0.85 | ADK (0.47) | ADKSRCEGFRFGFR2RET | |
| SCHEMBL27217643 | 0.85 | HASPIN (0.53) | ADKHASPINSRCEGFRMTOR | |
| SCHEMBL16236390 | 0.84 | ADK (0.54) | ADKSLC29A1SRCEGFRMTOR | |
| SCHEMBL29484542 | 0.84 | ADK (0.54) | ADKSLC29A1SRCEGFRMTOR | |
| SCHEMBL29503465 | 0.83 | SRC (0.52) | ADKSLC29A1SRCEGFRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472165-B1 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2023-09-06 | — | — | EP | disclosed |
| EP-3486244-A1 | NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-05-22 | — | — | EP | disclosed |
| EP-2878601-B1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | RIKEN (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-9604988-B2 | Agent for treating or inhibiting recurrence of acute myeloid leukemia | RIKEN (JP) | 2017-03-28 | — | — | US | disclosed |
| US-9540385-B2 | Pyrrolopyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160375026-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-29 | — | — | US | disclosed |
| US-20150239897-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS LLC | 2015-08-27 | — | — | US | disclosed |
| US-9096604-B2 | Pyrrolopyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9062058-B2 | — | — | 2015-06-23 | — | — | US | disclosed |
| EP-2878601-A1 | AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA | Riken (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-20140142126-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2475668-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029915-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375026-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, ZAP70 | ADK 601/4885SLC29A1 2737/4885HASPIN 903/4885 |
| US-20140142126-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | ADK 615/4885SLC29A1 3254/4885HASPIN 1184/4885 |
| US-20150210698-A1 | AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, BCOR, RUNX1 | ADK 2232/4885SLC29A1 2546/4885HASPIN 1115/4885 |
| US-20150239897-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | ADK 615/4885SLC29A1 3254/4885HASPIN 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.